Compare AGCO Corporation (AGCO) vs Eli Lilly And Co (LLY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AGCO Corporation vs Eli Lilly And Co — how do they compare? AGCO Corporation trades at $113.62 (market cap $8.24B), while Eli Lilly And Co trades at $1,223.13 (market cap $1.10T). The key difference: Eli Lilly And Co is far larger — about 133.5× AGCO Corporation's market cap, and AGCO Corporation pays the higher dividend (1.05%). Which is the better fit depends on your goals.
| AGCO | LLY | |
|---|---|---|
Market Cap | $8.24B | $1.10T |
Sector | Industrials | Health |
52-Week High | $140.49 | $1.24K |
52-Week Low | $100.14 | $625.65 |
Enterprise Value | $10.41B | $1.14T |
Dividend Yield | 1.05% | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGCO trades at $113.75, down 2.35% today, with a neutral technical signal and bullish moving averages. The company shows solid fundamentals with a P/E of 11.41 and net income margin of 7.43%, supported by three consecutive earnings beats. Recent news highlights marketing initiatives and fuel efficiency advancements, while cash flow improved to $249.10M in 2025 from negative levels in prior years.
The outlook remains positive with a consensus price target of $147.50, implying 30% upside, though risks include agricultural sector volatility and debt levels. Earnings momentum and valuation discounts present opportunities, but investor sentiment is balanced with equal buy/hold ratings from analysts.
Eli Lilly (LLY) trades at $1,235.56, up 2.07% today, with a bullish technical signal and strong earnings momentum, having beaten EPS estimates for three consecutive quarters. Revenue surged to $65.18B in 2025, with a net income margin of 34.99%, while analyst consensus is strongly positive with a $1,310 price target. Recent news highlights expansion in China for its breast cancer drug and bullish commentary from financial media on growth prospects.
The outlook remains favorable due to robust revenue growth and high profitability, though elevated valuation ratios and regulatory risks pose challenges. Upside is supported by analyst optimism and institutional interest, but investors should monitor competitive pressures and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AGCO Corporation
Agco is a global manufacturer of agricultural equipment. The company has five principal brands: Fendt, Massey Ferguson, Challenger, Valtra, and GSI. Unlike its competitors, Agco's product line extends beyond self-propelled equipment and implements by offering grain handling systems and livestock management solutions. Its products are available through a global dealer network, which includes over 3,200 dealer and distribution locations. Additionally, Agco offers both retail and wholesale financing to customers through its joint venture with Rabobank, a European food and agriculture focused bank.
Read more on AGCO →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
